Public Release: 

A potential targeting gene therapy for developing HCV

World Journal of Gastroenterology

Gene therapy has emerged as a novel approach to combat HCV infection in the last few years. However, one of the most important obstacles to overcome is "targeting": the appropriate genes must be delivered and expressed in HCV infected hepatocytes without harming normal tissues.

A research article to be published in the World Journal of Gastroenterology on July 7,2009 addresses this question. The research team led by Professor Feng from Central South University cloned the 2'-5'oligoadenylate synthetase (OAS) promoter and investigated its activity in the HCV-core positive liver cells. Since the role of HCV-core protein in modulating OAS gene expression is much controversial, this article further investigate the relationship of HCV-core protein and OAS promoter in human embryo hepatocyte line L02.

They established L02/core cell line that stably expressing HCV-core protein, and demonstrated that HCV core protein activated OAS gene promoter specifically and effectively. Utilization of OAS gene promoter would be an ideal strategy for developing HCV-specific gene therapy.


Reference: Wang Y, Mao SS, He QQ, Zi Y, Wen JF, Feng DY. Specific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: A potential for developing hepatitis C virus targeting gene therapy. World J Gastroenterol 2009; 15(25): 3178-3182

Correspondence to: De-Yun Feng, Department of Pathology, College of Basic Medical Sciences, Central South University, Changsha 410078, Hunan Province, China.

Telephone: +86-731-2650410 Fax: +86-731-2650408

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.